| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | 96.05% | 95.21% | 97.65% | 100.00% | 100.00% | — |
| Operating Margin | 50.09% | -37.50% | -46.86% | -64.03% | -69.52% | -113.39% | -78.56% | -43.70% | -33.07% | -159.67% | -454.58% | -393.79% |
| EBITDA Margin | 52.34% | -28.13% | -21.64% | -45.59% | -57.61% | -101.97% | -68.08% | -33.84% | -23.98% | -155.70% | -446.76% | -384.94% |
| Net Margin | 39.44% | -45.03% | -66.81% | -80.00% | -97.27% | -115.07% | -81.95% | -48.38% | -40.64% | -171.83% | -463.60% | -371.37% |
| Current Ratio | 2.35 | 2.35 | 2.02 | 1.71 | 1.87 | 4.44 | 3.30 | 1.92 | 3.04 | 5.27 | 7.84 | 9.96 |
| Quick Ratio | 2.27 | 2.31 | 1.97 | 1.65 | 1.84 | 4.37 | 3.22 | 1.83 | 2.90 | 5.23 | 7.84 | 9.96 |
| Debt / Equity | -1.40 | -0.26 | -0.35 | -1.65 | 300.02 | 0.64 | 0.53 | 0.44 | 0.93 | 0.82 | 0.42 | — |
| ROE | -332.49% | 33.08% | 76.55% | 161.06% | -36432.61% | -90.91% | -42.33% | -36.52% | -50.50% | -118.84% | -75.42% | -31.41% |
| ROA | 23.55% | -21.31% | -33.05% | -32.78% | -27.03% | -19.84% | -15.49% | -11.44% | -20.17% | -52.76% | -46.31% | -28.14% |
| Asset Turnover | 0.60 | 0.47 | 0.49 | 0.41 | 0.28 | 0.17 | 0.19 | 0.24 | 0.50 | 0.31 | 0.10 | 0.08 |
| Book Value / Share | -2.32 | -14.29 | -10.94 | -4.84 | 0.02 | 7.30 | 10.10 | 7.53 | 3.99 | 3.51 | 6.72 | 9.46 |
PTC Therapeutics, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing medicines for people living with rare and serious disorders. The company’s current portfolio centers on treatments for neurology and metabolism-related rare diseases, with approved therapies and additional product candidates spanning discovery, research, and clinical development. PTC Therapeutics also operates as a global life science business, combining internal research capabilities with commercialization expertise to support patients across children and adults. Its work is concentrated on clinically differentiated medicines aimed at addressing high unmet medical needs in specialized therapeutic areas. Based in Warren, New Jersey, PTC Therapeutics plays a meaningful role in the rare disease market through its diversified product pipeline and commercial operations.